by Jordana Choucair | Jan 13, 2023 | Life Sciences
Florida Governor Ron DeSantis announced a new legislative proposal that seeks to provide consumers more flexibility in buying prescription drugs and more information about their costs. The bill would specifically bar prescription benefit managers from forcing...
by Jordana Choucair | Jan 12, 2023 | Life Sciences
The U.S. Department of Health and Human Services (HHS) announced the specific timeline for the first year of Medicare prescription drug price negotiations. HHS will reveal in early September the first 10 high-cost drugs, and plans to negotiate the prices with drug...
by Jordana Choucair | Jan 12, 2023 | Life Sciences
Mark Cuban Cost Plus Drugs announced it will partner with pharmacy benefits manager RxPreferred Benefits to an effort to offer lower priced drugs through some employer-backed health insurance plans. Under the partnership, RxPreferred Benefits’ customers will have the...
by Jordana Choucair | Jan 11, 2023 | Life Sciences
The Food and Drug Administration (FDA) said its advisory panel will meet on February 15 to review Emergent Biosolutions Inc’s over-the-counter nasal spray to treat suspected opioid overdoses. Emergent is asking the FDA to approve for the prescription-free sale...
by Jordana Choucair | Jan 10, 2023 | Life Sciences
Moderna Inc. said it may price its COVID-19 vaccine between $110 and $130 per dose in the United States when commercial distribution begins. The price is similar to the price Pfizer Inc. is considering for its shot developed with BioNTech SE. While the price range is...
by Jordana Choucair | Jan 9, 2023 | Life Sciences
The Food and Drug Administration on Friday approved Leqembi – a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease. Eisai Co., the Japanese pharmaceutical company that developed the drug with Biogen Inc., said...
Recent Comments